Three years, a clinical hold and a death later, Sarepta abandons partnered pivotal-stage gene therapy
Sarepta is breaking off a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on its own as it prepares for a pivotal readout in mid-year.
According to Lysogene, Sarepta returned the global commercial rights for LYS-SAF302 after “unsuccessful discussions for transferring back to Lysogene the responsibility for the global commercial supply of LYS-SAF302.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.